Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Starton Therapeutics Inc. maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action currently in progress. This action is being reviewed by 1 distinct examiner, indicating a focused prosecution phase.
The examination is taking place within 1 distinct art unit, which matches the 1 distinct examiner involved. ELIZABETH ANNE MEYERS is the busiest examiner for this portfolio, holding 1 busiest examiner pending office action. Since the total pending office actions for the company is 1, this examiner is handling the entire active workload.
This concentration suggests that the company's current patenting efforts are specialized within a single technical domain. Practitioners will need to focus their efforts on the 1 distinct examiner, ELIZABETH ANNE MEYERS, who is the sole official reviewing the pending matter. The 1 pending office action represents a streamlined administrative path within the Biotechnology & Pharmaceuticals sector, requiring a targeted response to the 1 distinct art unit involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEYERS, ELIZABETH ANNE | 1 | 22.2% | +93.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17831603 | Transdermal Drug Delivery Systems for Administration of a Therapeutically Effective Amount of Lenalidomide and Other Immunomodulatory Agents | MEYERS, ELIZABETH ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17831603 | Transdermal Drug Delivery Systems for Administration of a Therapeutically Effective Amount of Lenalidomide and Other Immunomodulatory Agents | MEYERS, ELIZABETH ANNE | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17831603 | Transdermal Drug Delivery Systems for Administration of a Therapeutically Effective Amount of Lenalidomide and Other Immunomodulatory Agents | MEYERS, ELIZABETH ANNE | 1617 | §103DP | Non-Final OA | — | Pending | Jun 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialStarton Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Elizabeth Anne Meyers has the most, with 1 of Starton Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
